Search

ObjectiveTo explore the mechanism of microRNA-378a-3p (miR-378a-3p) affecting the development of breast cancer (BC) cells. MethodsThe expression of miR-378a-3p in BC cells based on the Cancer Genome Atlas Program database was analyzed. The starBase, miRDB, and miRWalk databases were used to predict the target genes of miR-378a-3p. Double-luciferase reporter experiments were performed to verify the targeted regulation of miR-378a-3p on NUAK family kinase 2 (NUAK2). Real-time fluorescence quantitative PCR and Western blot analyses were used to detect the expression of miR-378a-3p and NUAK2 mRNA and protein in BC cells. Cell proliferation ability was detected through cell-proliferation experiments. Cell scratch assay and invasion assay were used to detect the migration and invasion abilities of cells, respectively. Apoptosis and cell-cycle experiments were conducted to detect cell apoptosis rate and cell cycle distribution. ResultsThe expression of miR-378a-3p was significantly downregulated in BC cells, and miR-378a-3p overexpression inhibited the proliferation, migration, and invasion of BC cells. miR-378a-3p directly targeted NUAK2 and inhibited the mRNA and protein expression of NUAK2. ConclusionmiR-378a-3p inhibits the proliferation, migration, and invasion of BC cells by targeting NUAK2.

To investigate the effect of Suhuang Zhike capsule combined with thymosin in the treatment of elderly patients with COPD complicated with pulmonary infection and its influence on immune function and blood gas indexes. 80 elderly patients treated in hospital were studied. All patients were diagnosed with COPD disease and were complicated with pulmonary infection. The admission time of the patients was distributed from September 2020 to September 2023, and the patients were divided into groups according to different treatment methods, among which 40 patients were divided into matched group and thymosin treatment was added on the basis of conventional symptomatic treatment, and the other 40 patients were divided into observation group and Suhuang Zhike capsule was added on the basis of matched group. Compared the total therapeutic effective rate, inflammatory factors [C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α)] of the two groups, immune function [CD3+, CD4+ /CD8+ , Natural killer cell, NK)], blood gas index [partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen oxygen, PaO2), pH], occurrence of adverse reactions [nausea, vomiting, dizziness, rash, diarrhea]. The total response rate in the observation group was higher than that in the matched group (P<0.05). Post-treatment, the CRP and TNF- α levels in the observation group were significantly lower than those in the matched group (P<0.05). Post-treatment, the levels of CD3+, CD4+ /CD8+, and NK were higher in the observation group than in the matched group (P<0.05). After receiving treatment, the PaCO2 index level in the observation group was lower than that in the matched group (P<0.05), and the level of PaO2 and pH index in the observation group was higher than that in the matched group (P<0.05). The total incidence of adverse reactions such as nausea, vomiting, dizziness, rash and diarrhea in the two groups was 2.50% in the observation group and 7.50% in the matched group. There was no difference in the total incidence of adverse reactions between the two groups (P>0.05). In elderly patients with COPD complicated with pulmonary infection, the addition of Suhuang Zhike capsule on the basis of conventional symptomatic treatment and thymosin treatment can significantly improve the total effective rate of clinical treatment, improve the level of inflammatory factors and blood gas indexes, and enhance immune function, without increasing the risk of adverse reactions [ABSTRACT FROM AUTHOR]

Objective To explore the mechanism of microRNA-378a-3p (miR-378a-3p) affecting the deve- lopment of breast cancer (BC) cells. Methods The expression of miR-378a-3p in BC cells based on the Cancer Genome Atlas Program database was analyzed. The starBase, miRDB, and miRWalk databases were used to predict the target genes of miR-378a-3p. Double-luciferase reporter experiments were performed to verify the targeted regulation of miR-378a-3p on NUAK family kinase 2 (NUAK2). Real-time fluorescence quantitative PCR and Western blot analyses were used to detect the expression of miR-378a-3p and NUAK2 mRNA and protein in BC cells. Cell proliferation ability was detected through cell-proliferation experiments. Cell scratch assay and invasion assay were used to detect the migration and invasion abilities of cells, respectively. Apoptosis and cell-cycle experiments were conducted to detect cell apoptosis rate and cell cycle distribution. Results The expression of miR-378a-3p was significantly downregulated in BC cells, and miR- 378a-3p overexpression inhibited the proliferation, migration, and invasion of BC cells. miR-378a-3p directly targeted NUAK2 and inhibited the mRNA and protein expression of NUAK2. Conclusion miR-378a-3p inhibits the proliferation, migration, and invasion of BC cells by targeting NUAK2. [ABSTRACT FROM AUTHOR]

Objective To investigate the relationship between serum miR-199a-5p and miR-378a-3p levels and the recurrence of infants with proliferative facial hemangioma relapsed after propranolol withdrawal in infants. Methods Ninety-three infants with proliferative facial hemangioma were selected, all of whom received propranolol treatment. The recurrence of the hemangioma after treatment was followed up, and the children were divided into a recurrence group (23 patients) and a nonrecurrence group (70 patients). Venous blood was collected before and after treatment, and the serum levels of miR-199a-5p and miR-378a-3p were detected by qRT-PCR, and the relationship between the serum levels of miR-199a-5p and miR-378a-3p and the recurrence of proliferative facial hemangioma relapsed after propranolol withdrawal in infants was analyzed. Results The serum expressions levels of miR-199a-5p and miR-378a-3p in non-relapsed group were increased after treatment compared with before treatment (P < 0.05), and there was no significant difference in the levels of miR-199a-5p and miR-378a-3p in the serum of the recurrence group after treatment compared with before treatment (P > 0.05). After treatment, the levels of miR-199a-5p and miR-378a-3p in the serum of the recurrence group were lower than those of the nonrecurrence group (P < 0.05). After treatment, the serum levels of miR-199a-5p and miR-378a-3p in patients with Ⅲ ~Ⅳ Norm grade hemangioma were higher than those in patients with Ⅰ~Ⅱ Norm grade hemangioma (P < 0.05). Logistic regression analysis showed that the low expression of miR-199a-5p, low expression of miR-378a-3p and tumor grade Ⅰ~Ⅱ after treatment were risk factors for the recurrence of proliferative facial hemangioma after propranolol withdrawal in infants (P < 0.05). Conclusion Low serum levels of miR-199a-5p and miR-378a-3p are associated with the recurrence of proliferative facial hemangioma after propranolol withdrawal in infants.